+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Continuous Glucose Monitoring Market, Key Company Profiles, Technological Advancements, Competitive Landscape, Market Dynamics, Trends and Recent Developments - Global Forecast to 2035

  • PDF Icon

    Report

  • November 2026
  • Region: Global
  • iGATE Research
  • ID: 6293802
The global continuous glucose monitoring (CGM) market was valued at US$ 12.43 billion in 2025 and is projected to reach US$ 50.74 billion by 2035, reflecting the growing strategic importance of continuous glucose monitoring in diabetes management and preventive healthcare. CGM technology represents a significant advancement over conventional blood glucose monitoring, enabling continuous, real-time tracking of glucose fluctuations through a small sensor inserted beneath the skin. By measuring interstitial glucose levels and providing actionable insights into glucose trends, these systems support more informed treatment decisions, improve glycemic management, and reduce dependence on traditional fingerstick testing.

The escalating global burden of diabetes remains the primary structural driver of market growth. According to the World Health Organization (WHO), approximately 830 million people worldwide were living with diabetes in 2022, with the majority residing in low- and middle-income countries. The health consequences are equally significant: diabetes was directly responsible for approximately 2.0 million deaths in 2023, while 44% of diabetes-related deaths occurred among individuals below 70 years of age. Furthermore, diabetes contributed to approximately 390,000 kidney disease deaths, while elevated blood glucose levels were associated with around 10% of cardiovascular deaths. This growing disease burden is accelerating the need for more effective, technology-enabled diabetes management solutions. Against this backdrop, CGM systems are increasingly positioned as an integral component of modern diabetes care, offering continuous clinical insights, supporting personalized treatment strategies, and strengthening the shift toward proactive, data-driven disease management.

Government initiatives focused on diabetes awareness, prevention, and disease management are playing an important role in driving the continuous glucose monitoring (CGM) market. These programs promote regular glucose monitoring, encourage early intervention, and improve access to diabetes management resources. In the U.S., the Centers for Disease Control and Prevention (CDC) support several initiatives, including the National Diabetes Prevention Program (National DPP), which aims to prevent or delay type 2 diabetes through structured lifestyle interventions. Such efforts reinforce the importance of proactive disease management and technology-enabled monitoring.

The technological advancements in continuous glucose monitoring (CGM) devices are significantly contributing to market growth by improving sensor accuracy, wear duration, connectivity, and overall user experience. Modern sensors offer longer wear times and enhanced performance, reducing the frequency of replacements and improving patient convenience. For instance, Dexcom's Stelo Glucose Biosensor offers up to 15 days of wear with an additional 12-hour grace period. Meanwhile, smartphone integration and data-sharing capabilities enable real-time glucose tracking through connected devices and facilitate information sharing with healthcare providers. For example, Abbott's Freestyle Libre 2 system offers optional real-time alarms on smartphones, alerting users about their glucose levels. Furthermore, the integration of artificial intelligence (AI) and machine learning is expanding the analytical capabilities of CGM systems, enabling glucose trend identification, predictive insights, and more personalized diabetes management. Collectively, these innovations are strengthening clinical utility, improving patient engagement, and accelerating the adoption of advanced CGM solutions.

Recent Developments

  • In October 2026, Medtronic completed the separation of its diabetes business, MiniMed Group, Inc., establishing it as a fully independent company. Following the completion of the separation on October 15, 2026, Medtronic retained no equity stake in MiniMed, marking a significant strategic shift in the diabetes technology market.
  • In August 2026, Abbott Laboratories received U.S. Food and Drug Administration (FDA) authorization for its Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System. The wearable device continuously monitors glucose and ketone levels, helping detect rising ketones that may lead to diabetic ketoacidosis (DKA). Intended for individuals with diabetes aged 2 years and older, the system offers up to 10 days of sensor wear, representing a significant advancement in continuous metabolic monitoring.
  • In April 2025, Dexcom received U.S. Food and Drug Administration (FDA) clearance for its Dexcom G7 15 Day Continuous Glucose Monitoring System for adults aged 18 years and older with diabetes in the United States.

By Component: Global Continuous Glucose Monitoring Market - Key Takeaways

  • The sensors segment is expected to dominate the continuous glucose monitoring (CGM) devices market throughout the forecast period, driven by the growing adoption of CGM systems and the critical role of sensors in continuous glucose measurement. Technological advancements in sensor accuracy, reliability, miniaturization, and wear duration are further supporting segment growth. Modern sensors increasingly achieve mean absolute relative difference (MARD) values below 10%, improving measurement precision and clinical confidence. For instance, Dexcom G7 features a compact design and offers up to 10 days of sensor wear, enhancing user comfort and convenience.
  • The receiver segment is expected to witness significant growth over the forecast period, supported by increasing adoption of digital diabetes management solutions. Receivers, also known as readers, display real-time glucose readings and trends transmitted by CGM sensors through dedicated handheld devices or compatible smartphone applications. Leading manufacturers, including Dexcom and Abbott, offer dedicated receivers for selected CGM systems, providing an alternative for patients who do not have access to compatible smartphones. Growing demand for convenient glucose data visualization and monitoring is expected to support segment expansion.

By Connectivity: Global Continuous Glucose Monitoring Market - Key Takeaways

  • Based on connectivity, the Bluetooth segment dominated the continuous glucose monitoring (CGM) market in 2025. Bluetooth Low Energy (BLE) technology enables compatible CGM sensors to automatically transmit glucose readings to smartphones and dedicated receivers, allowing users to monitor glucose levels in real time. The collected data can also be shared with cloud-based platforms and healthcare providers through connected devices using cellular networks or Wi-Fi. Semiconductor companies, including Nordic Semiconductor, Renesas Electronics, and onsemi, develop wireless connectivity and sensor-related technologies that support medical device applications. Continuous advancements in wireless communication, data reliability, and digital health integration are strengthening the adoption of Bluetooth-enabled CGM systems.
  • The 4G/Cellular connectivity segment is anticipated to witness the fastest growth in the continuous glucose monitoring market over the forecast period. Increasing demand for remote patient monitoring and connected diabetes management solutions is supporting the adoption of cellular connectivity. By enabling smartphones and compatible monitoring devices to transmit glucose readings to cloud-based platforms through cellular networks, including 4G, this technology facilitates remote data access, real-time monitoring, and information sharing with healthcare professionals and caregivers. These capabilities improve accessibility to glucose information, support timely clinical interventions, and strengthen the integration of CGM systems into digital healthcare ecosystems. Growing adoption of telehealth and remote monitoring solutions is expected to further accelerate segment growth.

By Age: Global Continuous Glucose Monitoring Market - Key Takeaways

  • The adult segment dominated the continuous glucose monitoring (CGM) market in 2025, supported by the high prevalence of diabetes and increasing adoption of advanced glucose monitoring technologies. The American Diabetes Association's 2026 Standards of Care recommend CGM for older adults with type 1 diabetes and those with type 2 diabetes receiving insulin therapy, highlighting its benefits in improving glycemic outcomes, reducing hypoglycemia, and lowering treatment burden.
  • The children segment accounted for the second-largest share in 2025. In June 2026, the U.S. FDA cleared Dexcom's Stelo Glucose Biosensor System for OTC use in individuals aged 2 years and older who do not use insulin, expanding access to wearable glucose monitoring among pediatric users. This development is expected to support awareness and adoption of CGM technology among children and their caregivers.
  • The senior segment also represents an important user group, with growing emphasis on reducing hypoglycemia risks, simplifying diabetes management, and improving access to continuous monitoring solutions.

By Indication: Global Continuous Glucose Monitoring Market - Key Takeaways

  • Based on indication, the Type 1 diabetes segment dominated the continuous glucose monitoring market in 2025. People suffering from Type 1 diabetes (T1D) are the primary users of CGM devices, owing to their lifelong requirement for insulin and the critical need to tightly regulate glucose levels. CGM systems provide real-time glucose readings, trend analysis, and automated alerts, enabling more precise insulin management and improved glycemic control. According to the Type 1 Diabetes Index, over 1.5 million people are living with type 1 diabetes in the United States in 2025. Each year about 52,563 people are newly diagnosed and 13,349 people with T1D die. T1D management demands frequent blood glucose monitoring and precise insulin dosing. Real-time CGM data is integral to achieving glycemic targets and reducing acute complications.
  • The Type 2 diabetes segment is expected to register fastest growth over the forecast period, driven by rising disease prevalence, expanding clinical applications, and improving access to glucose monitoring technologies. Adoption is increasingly extending beyond insulin-dependent patients toward individuals managing Type 2 diabetes through oral medications and lifestyle modifications. Reimbursement developments are also supporting market expansion. In April 2023, Medicare expanded CGM coverage eligibility to include certain non-insulin-treated individuals with documented problematic hypoglycemia. Additionally, the FDA's March 2024 clearance of Dexcom's Stelo as an over-the-counter CGM for adults aged 18 years and older who do not use insulin created a new access channel for consumers. These developments, alongside growing emphasis on proactive diabetes management, are expected to accelerate CGM adoption among a broader population of people with diabetes.

By End-Use: Global Continuous Glucose Monitoring Market - Key Takeaways

  • Based on end-use, the homecare segment dominated the continuous glucose monitoring (CGM) market in 2025, driven by the growing adoption of long-term, patient-centered diabetes management solutions. CGM systems enable continuous glucose tracking, real-time alerts, and early identification of hypo- and hyperglycemic events, supporting effective disease management outside clinical settings. The shift toward decentralized healthcare and home-based monitoring is further accelerating adoption, particularly among individuals requiring long-term diabetes management. Additionally, advancements in sensor usability, wireless connectivity, smartphone integration, and cloud-based data sharing are strengthening the segment's growth. These capabilities allow patients and caregivers to monitor glucose trends while enabling healthcare professionals to remotely assess readings and adjust treatment strategies.
  • The hospitals & clinics segment is expected to register fastest growth during the forecast period, driven by increasing interest in technology-enabled inpatient diabetes management. Healthcare institutions are increasingly exploring CGM systems to support continuous glucose tracking, identify glycemic fluctuations, and complement conventional point-of-care testing among hospitalized patients with diabetes. The growing emphasis on improving glycemic control, reducing monitoring burden, and enabling timely clinical interventions is supporting adoption.

By Region: Global Continuous Glucose Monitoring Market - Key Takeaways

  • North America dominated the global continuous glucose monitoring (CGM) market in 2025, supported by advanced healthcare infrastructure, high healthcare expenditure, favorable access to innovative medical technologies, and strong adoption of digital diabetes management solutions. The United States represents the primary growth contributor, driven by the substantial diabetes burden, established reimbursement frameworks, and the presence of leading CGM manufacturers. According to the Centers for Disease Control and Prevention (CDC), approximately 40.1 million Americans, representing 12% of the population, were living with diabetes in 2023, including 2.1 million individuals with Type 1 diabetes. The growing patient population, combined with increasing awareness, technological innovation, and expanding access to continuous glucose monitoring, continues to strengthen North America's position in the global market.
  • Europe accounted for the second-largest share of the global continuous glucose monitoring (CGM) market in 2025, driven by its substantial diabetes burden, established healthcare infrastructure, and growing adoption of digital health technologies. Technological advancements, including improved wearable sensors, real-time glucose monitoring, longer sensor wear duration, and smartphone integration, are further supporting regional market growth. Germany represents a key market, supported by its large diabetic population and advanced healthcare system. According to the International Diabetes Federation (IDF), approximately 6.5 million adults in Germany were living with diabetes in 2024, highlighting the significant need for effective glucose management solutions. Increasing focus on diabetes prevention, early diagnosis, and improved disease management is expected to further support CGM adoption across the country.
  • Asia-Pacific is expected to register significant growth in the continuous glucose monitoring market over the forecast period, driven by the rising prevalence of diabetes, increasing health awareness, and improving access to advanced healthcare technologies. Countries such as China, India, and Japan are witnessing growing demand for CGM solutions, supported by expanding healthcare infrastructure and greater adoption of digital diabetes management. Furthermore, government initiatives focused on strengthening diabetes care, improving disease awareness, and expanding access to healthcare services are expected to create additional growth opportunities across the region.
  • The Latin America continuous glucose monitoring market is gaining momentum, driven by the rising prevalence of diabetes and other metabolic disorders, increasing urbanization, lifestyle changes, and an aging population. The growing burden of Type 1 and Type 2 diabetes is strengthening demand for real-time glucose monitoring solutions to support long-term disease management and reduce the risk of complications. Additionally, rising awareness of early glucose detection and preventive diabetes care, supported by public health programs, educational campaigns, and healthcare initiatives, is expected to encourage wider adoption of CGM devices across the region.

Global Continuous Glucose Monitoring Market - Competitive Landscape

  • Abbott Laboratories dominated the global continuous glucose monitoring market in 2025, supported by its extensive FreeStyle Libre product portfolio, strong global presence, and competitive pricing. The FreeStyle Libre platform has achieved widespread adoption due to its ease of use, convenient wearable sensors, and integration with digital health platforms. Abbott continues to strengthen its market position through product innovation, real-time glucose monitoring capabilities, and cloud-based data management solutions that support personalized diabetes care.
  • Dexcom is another leading player in the global CGM market, recognized for its advanced continuous glucose monitoring systems, including the Dexcom G7 platform. The company focuses on improving sensor accuracy, simplifying device application, and expanding connectivity with smartphones, insulin pumps, and digital health applications. Its integration with automated insulin delivery systems further strengthens its position in technology-driven diabetes management.
  • Medtronic also maintains a significant presence through its Guardian CGM technology and integrated insulin delivery solutions. The company's MiniMed systems combine continuous glucose monitoring with insulin pumps and automated insulin delivery capabilities, supporting personalized insulin management and improved glycemic control. Continued product innovation and integration of connected diabetes care technologies remain central to the competitive strategies of these companies.
This report provides a comprehensive analysis of the Global Continuous Glucose Monitoring Market.

This report has been analyzed from 13 View Points:

  • Global - Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
  • Global - Continuous Glucose Monitoring Market Share and Forecast (2022 - 2035)
  • By Component - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
  • By Connectivity - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
  • By Age - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
  • By Indication - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
  • By End Use - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
  • By Region - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
  • By Country - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
  • Global Continuous Glucose Monitoring Market - Technological Advancements
  • Global Continuous Glucose Monitoring Market - Key Company Profiles and Analysis
  • Global Continuous Glucose Monitoring Market - Trends & Recent Developments
  • Global Continuous Glucose Monitoring - Market Dynamics

By Component: Global Continuous Glucose Monitoring Market and Forecast

  • Transmitters
  • Sensors
  • Receivers

By Connectivity: Global Continuous Glucose Monitoring Market and Forecast

  • Bluetooth
  • 4G/Cellular
  • Others

By Age: Global Continuous Glucose Monitoring Market and Forecast

  • Children
  • Adults
  • Senior

By Indication: Global Continuous Glucose Monitoring Market and Forecast

  • Type 1 diabetes
  • Type 2 diabetes
  • Gestational Diabetes
  • Prediabetes & Preventive Monitoring

By End-Use: Global Continuous Glucose Monitoring Market and Forecast

  • Homecare settings
  • Hospitals & Clinics
  • Others

By Region: Global Continuous Glucose Monitoring Market and Forecast

1. North America
  • United States
  • Canada
  • Mexico
2. Europe
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Russia
  • Hungary
  • Poland
  • Rest of Europe
3. Asia Pacific
  • China
  • Japan
  • India
  • Australia and New Zealand
  • South Korea
  • Vietnam
  • Rest of Asia Pacific
4. Latin America
  • Brazil
  • Chile
  • Rest of Latin America
5. Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Rest of Middle East and Africa

Global Continuous Glucose Monitoring Market - Key Company Profiles

1. Abbott Laboratories
2. A. Menarini Diagnostics
3. Dexcom
4. i-SENS
5. F. Hoffmann-La Roche
6. Med Trust
7. Medtronic
8. Medtrum Technologies
9. Senseonics
10. Sibionics
11. Sinocare
12. Zhejiang POCTech
13. Ascensia Diabetes Care Holdings

Table of Contents

1. Executive Summary
2. Research Methodology
2.1 Research Design
2.2 Research Approach
2.3 Data Collection Methods
2.4 Market Assumptions
3. Global - Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
4. Global - Continuous Glucose Monitoring Market Share and Forecast (2022 - 2035)
4.1 By Component - Global Continuous Glucose Monitoring Market Share and Forecast
4.2 By Connectivity - Global Continuous Glucose Monitoring Market Share and Forecast
4.3 By Age - Global Continuous Glucose Monitoring Market Share and Forecast
4.4 By Indication - Global Continuous Glucose Monitoring Market Share and Forecast
4.5 By End Use - Global Continuous Glucose Monitoring Market Share and Forecast
4.6 By Region - Global Continuous Glucose Monitoring Market Share and Forecast
4.7 By Company - Global Continuous Glucose Monitoring Market Share and Forecast
5. By Component - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
5.1 Global CGM - Transmitters Market and Forecast
5.2 Global CGM - Sensors Market and Forecast
5.3 Global CGM - Receivers Market and Forecast
6. By Connectivity - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
6.1 Global CGM - Bluetooth Market and Forecast
6.2 Global CGM - 4G/Cellular Market and Forecast
6.3 Global CGM - Others Market and Forecast
7. By Age - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
7.1 Global CGM - Children Market and Forecast
7.2 Global CGM - Adults Market and Forecast
7.3 Global CGM - Senior Market and Forecast
8. By Indication - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
8.1 Global CGM - Type 1 Diabetes Market and Forecast
8.2 Global CGM - Type 2 Diabetes Market and Forecast
8.3 Global CGM - Gestational Diabetes Market and Forecast
8.4 Global CGM - Prediabetes & Preventive Monitoring Market and Forecast
9. By End Use - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
9.1 Global CGM - Homecare Settings Market and Forecast
9.2 Global CGM - Hospitals & Clinics Market and Forecast
9.3 Global CGM - Others Market and Forecast
10. By Region - Global Continuous Glucose Monitoring Market and Forecast (2022 - 2035)
10.1 North America - Continuous Glucose Monitoring Market and Forecast
10.1.1 United States - Continuous Glucose Monitoring Market and Forecast
10.1.2 Canada - Continuous Glucose Monitoring Market and Forecast
10.1.3 Mexico - Continuous Glucose Monitoring Market and Forecast
10.2 Europe - Continuous Glucose Monitoring Market and Forecast
10.2.1 Germany - Continuous Glucose Monitoring Market and Forecast
10.2.2 United Kingdom - Continuous Glucose Monitoring Market and Forecast
10.2.3 France - Continuous Glucose Monitoring Market and Forecast
10.2.4 Spain - Continuous Glucose Monitoring Market and Forecast
10.2.5 Italy - Continuous Glucose Monitoring Market and Forecast
10.2.6 Russia - Continuous Glucose Monitoring Market and Forecast
10.2.7 Hungary - Continuous Glucose Monitoring Market and Forecast
10.2.8 Poland - Continuous Glucose Monitoring Market and Forecast
10.2.9 Rest of Europe - Continuous Glucose Monitoring Market and Forecast
10.3 Asia Pacific - Continuous Glucose Monitoring Market and Forecast
10.3.1 China - Continuous Glucose Monitoring Market and Forecast
10.3.2 Japan - Continuous Glucose Monitoring Market and Forecast
10.3.3 India - Continuous Glucose Monitoring Market and Forecast
10.3.4 Australia and New Zealand - Continuous Glucose Monitoring Market and Forecast
10.3.5 South Korea - Continuous Glucose Monitoring Market and Forecast
10.3.6 Vietnam - Continuous Glucose Monitoring Market and Forecast
10.3.7 Rest of Asia Pacific - Continuous Glucose Monitoring Market and Forecast
10.4 Latin America - Continuous Glucose Monitoring Market and Forecast
10.4.1 Brazil - Continuous Glucose Monitoring Market and Forecast
10.4.2 Chile - Continuous Glucose Monitoring Market and Forecast
10.4.3 Rest of Latin America - Continuous Glucose Monitoring Market and Forecast
10.5 Middle East & Africa - Continuous Glucose Monitoring Market and Forecast
10.5.1 Saudi Arabia - Continuous Glucose Monitoring Market and Forecast
10.5.2 South Africa - Continuous Glucose Monitoring Market and Forecast
10.5.3 UAE - Continuous Glucose Monitoring Market and Forecast
10.5.4 Turkey - Continuous Glucose Monitoring Market and Forecast
10.5.5 Rest of Middle East & Africa - Continuous Glucose Monitoring Market and Forecast
11. Global Continuous Glucose Monitoring Market - Technological Advancements
12. Global Continuous Glucose Monitoring Market - Key Company Profiles
12.1 Abbott Laboratories
12.2 A. Menarini Diagnostics
12.3 Dexcom
12.4 i-SENS
12.5 F. Hoffmann-La Roche
12.6 Med Trust
12.7 Medtronic
12.8 Medtrum Technologies
12.9 Senseonics
12.10 Sibionics
12.11 Sinocare
12.12 Zhejiang POCTech
12.13 Ascensia Diabetes Care Holdings
13. Global Continuous Glucose Monitoring Market - Trends & Recent Developments
14. Global Continuous Glucose Monitoring - Market Dynamics
14.1 Global Continuous Glucose Monitoring Market - Drivers
14.2 Global Continuous Glucose Monitoring Market - Challenges

Companies Mentioned

  • Abbott Laboratories
  • A. Menarini Diagnostics
  • Dexcom
  • i-SENS
  • F. Hoffmann-La Roche
  • Med Trust
  • Medtronic
  • Medtrum Technologies
  • Senseonics
  • Sibionics
  • Sinocare
  • Zhejiang POCTech
  • Ascensia Diabetes Care Holdings